Physician
Parker, Jonathan
Parker, Jonathan was paid $4.30M by Medicaid between Jan 2018 and Dec 2024, across 42 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 59% of everything it billed.
33Billing provider infoPARKER, JONATHAN
BATAVIA, IL 60510
BATAVIA, IL 60510
33aNPI1548309982assigned 02/05/2007
33bProvider typeFamily Medicine Physician
28Total paid$4.30M
24GClaims80,420
24DCodes billed42
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Illinois
Rank by total paid#17 of 2,947
Median peer was paid$43K
This provider vs. median101×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 731 | $28K | |
| 2019 | 2,876 | $150K | |
| 2020 | 6,009 | $358K | |
| 2021 | 6,454 | $360K | |
| 2022 | 14,404 | $718K | |
| 2023 | 23,325 | $1.10M | |
| 2024incomplete | 26,621 | $1.58M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 59% | 33,094 | 26,667 | $2.55M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 21% | 11,106 | 9,981 | $883K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 5.1% | 6,332 | 5,749 | $220K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.0% | 8,395 | 7,388 | $128K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.5% | 3,008 | 2,802 | $109K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.3% | 768 | 731 | $97K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.1% | 260 | 249 | $89K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.6% | 1,789 | 1,664 | $69K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,702 | 1,788 | $29K |
| 36410 | <1% | 1,505 | 1,150 | $22K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 305 | 299 | $15K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,241 | 950 | $14K |
30 more codes
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 381 | $12K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 364 | $9K |
| 81002 | <1% | 2,728 | $7K | |
| 93000 | <1% | 296 | $6K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 328 | $5K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 72 | $5K |
| 87807 | <1% | 486 | $5K | |
| 73610 | <1% | 185 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 81 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,782 | $4K |
| 73630 | <1% | 149 | $3K | |
| 81025 | <1% | 473 | $3K | |
| 87420 | <1% | 112 | $2K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 132 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 164 | $1K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 83 | $1K |
| 86308 | <1% | 214 | $991.64 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 44 | $659.38 |
| 73140 | <1% | 25 | $496.05 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 254 | $484.04 |
| 87486 | <1% | 12 | $421.08 | |
| 87581 | <1% | 12 | $421.08 | |
| 73110 | <1% | 14 | $310.80 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 26 | $307.21 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 52 | $268.35 |
| 73562 | <1% | 12 | $249.76 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,283 | $194.99 |
| 81000 | <1% | 63 | $162.44 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 67 | $70.27 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 21 | $7.11 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.